

Scientific Program: *For sponsored program, prior registration is needed."

Special program.

ISTH educational Program

- **ISTH educational program I: Day 1 (5/28), 16:00 – 18:00, Room 4**

"Risk factors and prevention of thrombosis" (WTD steering committee event)

Chairs: Eriko Morishita (Japan), Jean Connors (USA)

1. A Global survey for the World Thrombosis Day 2025. Marcello Di Nisio (Italy)
2. Tentative Plan for Therapeutic Guideline on Hereditary Thrombotic disorders. Beverley Hunt (UK)
3. Cancer associated thrombosis. Dr. Masataka Ikeda (Japan)

- **ISTH educational program II: Day 2 (5/29), 15:30 – 18:00, Room 4**

"Congenital and acquired hemorrhagic disorders"

Chairs: Teruto Hashiguchi, Tetsumei Urano (Japan)

1. Recent advances in Hemophilia therapy. Keiji Nogami (Japan)
2. Immune thrombocytopenia (ITP). Hisashi Kato (Japan)
3. Laboratory and clinical aspects of Factor XI deficiency. Chee We Tan (Australia)
4. Acquired FXIII deficiency. Teruto Hashiguchi (Japan)
5. Rare bleeding disorders due to hyperfibrinolysis: PAI-1 deficiency & TM/TAFI abnormality. Tetsu Urano (Japan)

APSTH 2026 Educational Program

- **Program I: Day 1 (5/28), 11:30-13:00, Event Hall**

Chairs: Yukio Ozaki & Satoshi Fujii (Japan)

1. Welcome message from APSTH2026 Presidents. Tetsumei Urano & Teruto Hashiguchi (Japan)
2. APSTH and its regional role: challenges and opportunities. Satoshi Fujii (Japan)
3. Understanding hemostasis. Jameela Sathar (Malaysia)
4. Coagulation and hemostasis testing. Chee Wee Tan (Australia)

- **Program II: Day 2 (5/29), 9:00-10:30, Event Hall**

Early career forum

Facilitators: Azusa Nagao, Kazuya Sakai, Teruto Hashiguchi, Tetsumei Urano (Japan)

Keynote Speech (10 min. each)

1. Preparing for a Career in Thrombosis and Hemostasis: The world has become much smaller. Spero Cataland (USA)
2. Advocacy and changing governmental and/or health service policy. Beverley Hunt (UK)
3. Standing on the Shoulders of Giants: My Journey Through TTP Research. Kazuya Sakai (Japan)
4. How to Balance Research, Career, and Parenting. Azusa Nagao (Japan)
5. open forum (50 min.)

- **Program III: Day 3 (5/30), 9:00-11:00, Event Hall**

Chairs: Ng Heng Joo (Singapore) & Soo-Mee Bang (Korea)

1. Approach to thrombosis and thrombophilia. Ng Heng Joo (Singapore)
2. Management of anticoagulation in women. Lee Lai Heng (Singapore)
3. How to approach patients with bleeding tendency. Munekazu Yamakuchi (Japan)
4. Measuring Success: Outcome Assessment for Novel Hemophilia Therapies. Sheng-Chieh Chou (Taiwan)

JSTH/APSTH Joint Symposium Day 1 (5/28) 9:20-11:20, Room 3

Chairs: Tsukasa Ohmori, Keiji Nogami, Teruto Hashiguchi (Japan)

1. Pathogenic Alterations in CD4+ T and B Cells in Acquired Hemophilia A via scRNA-seq. Enhao Li, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, China
2. Engineering platelets with Dab2 expression for efficient hemostasis in thrombocytopenia. Ching-Ping Tseng, 1Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Children's Medical Center, Taichung Veterans General Hospital, Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Department of Medical Laboratory Science and Biotechnology, China Medical University, Taiwan
3. Novel alternatively spliced human Protein Z isoform with predicted coagulation relevance. Sayeed ur Rehman Abul Kalam, Department of Biochemistry, Jamia Hamdard, India
4. Therapeutic Base Editing to Generate a Gain-of-function F9 variant for Hemophilia B. Nemekhbayar Baatartsogt, Department of Biochemistry, Center for Gene Therapy Research, Jichi Medical University, Tochigi, Japan
5. Factor XI localization in human deep venous thrombus and function of activated factor XI on venous thrombus formation and hemostasis. Nobuyuki Oguri, Department of Pathology, Faculty of medicine, University of Miyazaki, Department of Diagnostic Pathology, Miyazaki Medical Association Hospital, Japan
6. Molecular Analysis of a Novel FVIII Variant (FVIII-Nara) Identified in a Patient with Moderate Hemophilia A. Shoko Furukawa, Department of Pediatrics, Nara Medical University, Division of Hemophilia, Osaka National Hospital, Japan

Sponsored seminars (Prior registration is needed)

Luncheon seminars

• **Day 1 (5/28) 13:00-13:50**

LS1: Room 4 [Registration](#) available here

Acquired Hemophilia and NovoSeven®: Time to Update a Long-Standing Therapeutic Choice

Chair: Dr. Teruto Hashiguchi (Kagoshima University Director and Vice President)

Speaker: Dr. Keiji Nogami (Department of Pediatrics, Nara Medical University Professor)

Novo Nordisk Pharma Ltd.

LS2: Room 5 [Registration](#) available here

Pitfalls in Diagnosing TTP: Lessons from Atypical Presentations

Chair: Dr. Masataka Ishimura (Department of pediatrics, graduate of medical sciences, Kyushu University Japan)

Speaker: Dr. Kazuya Sakai (Nara Medical University, Department of Transfusion Medicine, Japan)

Takeda Pharmaceutical Company Limited

Day 2 13:30-14:20

LS3: Room 4 [Registration](#) available here

The Changing Landscape of TTP Management

Chair: Dr. Masanori Matsumoto (Department of Hematology and Blood Transfusion Medicine, Nara Medical University)

Speaker: Dr. Spero Cataland (Division of Hematology, Department of Internal Medicine, Ohio State University Medical Center)
Sanofi K.K.

Day 3 13:30-14:20

LS4: Room 3 [Registration](#) available here

The Eight Year Journey of Efficizumab: Evidence from Bench to Bedside

Chair: Dr. Rie Shirayama (University of Occupational and Environmental Health)

Speaker: Dr. Zenjiro Sampei (Chugai Pharmaceutical Co., Ltd.) / Ryuui Miyashita (Tokyo Medical University / Clinical Laboratory Medicine)

Chugai Pharmaceutical Co., Ltd.

Sweet's seminar

Day 1 15:00-15:50

SS1: Room 5 [Registration](#) available here

Impact of EHL-FIX and Evolving Patient Needs in Hemophilia B in Japan

Chair: Dr. Yeu-Chin Chen (Hemophilia Care & Research Center, Tri-Service General Hospital)

Speaker: Dr. Ei Kinai (Department of Laboratory Medicine, Tokyo Medical University)

CSL Behring K.K.

General scientific program

Oral sessions 1-9

Day 1 (5/28) afternoon

1. Venous thrombosis 14:00-15:00, Room 3

Chairs: Lai Heng Lee (Singapore) & Jameela Sathar (Malaysia)

[Abstracts available here](#)

1. Automatic Segmentation and Quantification of Cerebral Venous Thrombus. Xiao xu Yang (China)
2. Population-specific ABO haplotypes reveal distinct VTE risk in East Asians. Haobo Li (China)
3. Association of markers of coagulation, fibrinolysis and inflammation with PTS. Worapapas Chalerm suwiwattanakan (Thailand)
4. Prediction Risk factors for portal vein thrombosis and time to portal hypertension. Patcharee Komvilaisak (Thailand)
5. Long COVID alopecia: inflammation, coagulation and fibrinolysis, and keratinocyte injury. Satomi Nagaya (Japan)

2. Hemophilia I 14:00-15:00, Room 4

Chairs: Shyh-Shin Chiou (Taiwan) & Keiji Nogami (Japan)

[Abstracts available here](#)

1. Noninversion Variants in Sporadic Hemophilia A: An Origin, Inheritance and Timing Study. Shih-Yao Lin (Taiwan)
2. Utility of Next-Generation Sequencing in the Genetic Diagnosis of Hemophilia. Chepsy Philip (India)
3. Pre-existing Neutralizing Antibodies to AAV3B, AAV5, and AAV8 in Mongolian Hemophilia. Nemekhbayar Baatartsogt (Japan)
4. Spectrum of F8 Gene Mutations and Inhibitor Risk in Patients with Hemophilia

A. Tuan Nguyen (Viet Nam)

5. Clinical and Treatment Outcomes of Congenital Factor VII Deficiency in Children. Tuan Nguyen (Viet Nam)

3. Pathogenesis I 14:00-15:00, Room 5

Chairs: Shuwaha Lin (Taiwan) & Tsukasa Ohmori (Japan)

[Abstracts available here](#)

1. Characterization and Regenerative Efficacy of Platelet-Rich Plasma-Derived Exosomes. Soo chong Kim (Japan)
2. Basic Study on VWF Induced by Low-Dose Colchicine in Vascular Endothelial Cells. Akito Tabaru (Japan)
3. Exome-Wide Association Study of Idiopathic Recurrent Pregnancy Loss. Hyeon Woo Park (Republic of Korea)
4. Thrombomodulin enhances tumor progress via ezrin- and FAK-dependent cancer cell plasticity. Cheng-Hsiang Kuo (Taiwan)
5. Thrombomodulin as a Multi-Domain Regulator of Neovascularization. Hua-Lin Wu (Taiwan)

4. Arterial diseases 15:00-16:00, Room 4

Chairs: Raymond Wong (Hong Kong) & Jiaan-Der Wang (Taiwan)

[Abstracts available here](#)

1. The role of CD93 in abdominal aortic aneurysm. Chao-Han Lai (Taiwan)
2. Whole Blood Viscosity in Ischemic Heart Disease: Single-Center Pilot Investigation. Jung Rae Cho (Republic of Korea)
3. Erythrocytosis is associated with cardiovascular disease: The Shizuoka Study. Aya Shoji-Asahina (Japan)
4. Impact of miR-21 Gene Polymorphisms on Plasma Exosomal miRNA Profiles in Ischemic Stroke. Hyeon Woo Park (Republic of Korea)
5. OACs to Prevent Stroke in AF Patients After Prior Intracranial Hemorrhage: Meta-analysis. Mohamed Hamouda Elkasaby (Egypt)

Day 2 (5/29) afternoon

5. Platelets 14:30-15:30, Room 4

Chairs: Yukio Ozaki (Japan) & Joyce Lam (Singapore)

[Abstracts available here](#)

1. Antiplatelet effects of spironolactone through regulation of thromboxane A2 generation. Seongmo Yang (Republic of Korea)
2. Refractory ITP Revisited: MYH9-Related Disorder with Multisystem Involvement. Wan Alina Khadijah Wan Nik Ahmad Mustafa (Malaysia)
3. Efficacy of Low-Dose Rituximab in Patients with Immune Thrombocytopenia: A Meta-Analysis. April Joy Ong (Philippines)
4. Platelet Dysfunction Due to CalDAG-GEFI Abnormalities. Tsuyoshi Kojo (Japan)

Day 3 (5/30) afternoon

1. Clinical Manifestations in the Prospective Cohort of the Korean Bleeding Disorder Registry. Jung Woo Han (Republic of Korea)
2. DOACs in Pediatric Congenital and Acquired Heart Disease: Meta-Analysis. Mohamed Hamouda Elkasaby (Egypt)
3. Iron Therapy and Thrombotic Outcomes in CKD: A Systematic Review and Meta-analysis. Caryn Louise Gutierrez (Philippines)
4. Bleeding and Mortality Outcomes of Warfarin vs DOAC Emergency Reversal in an Asian Cohort. Hock Peng Koh (Malaysia)
5. Antithrombotic Strategies in Atrial Fibrillation With Chronic Coronary Syndrome. Hendrianus Hendrianus (Indonesia)

Poster Sessions I & II

Poster session I Day 1 (5/28) - Day 2 (5/29) (poster manning Day 2 (5/29) 12:00-13:00)

1. Hemophilia
2. Bleeding
3. New strategies (laboratory test)

[Abstracts available here](#)

Poster session II Day 2 (5/29)- Day 3 (5/30) (poster manning Day 3 (5/30) 12:45-13:30)

1. Thrombosis
2. TTP
3. Coagulation, fibrinolysis & platelets
4. New strategies (therapy)

[Abstracts available here](#)